Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed ...
Zacks Investment Research on MSN
Merck's non-oncology drugs Q4 performance: What to expect
As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
The Chosun Ilbo on MSN
Obesity treatments overtake Keytruda as top-selling drugs
Obesity treatments are reshaping the global pharmaceutical and biotech market landscape. Recent preliminary figures show that ...
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.
Gilead has announced full results from its study of Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) as a first ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...
Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results